Department of Health | HIV, STD, and TB Services | Congenital Syphilis
New Antibiotics Could Tackle Drug-resistant Tuberculosis Bacteria
Infection by Mycobacterium tuberculosis kills 1.5 million people worldwide every year. Antibiotics to treat TB exist, but in recent years, multi-drug resistant (MDR), extensively drug-resistant (XDR) and totally drug-resistant (TDR) strains of the bacterium have developed. According to a new study publishing May 31st in the open-access journal PLOS Biology by Ho-Yeon Song of Soonchunhyang University in the Republic of Korea and colleagues, a new class of antibiotics is highly effective against drug-resistant tuberculosis. If validated in clinical trials, the new drug class would represent a major advance in the treatment of tuberculosis.
To develop new drug candidates, the authors first screened a wide variety of plant extracts and found one with particularly promising antibacterial activity. Deoxypergularinine (DPG) is purified from the root of Cynanchum atratum, a flowering plant used in traditional Chinese medicine. The researchers proceeded to make and test multiple analogues of DPG for their ability to inhibit M. Tuberculosis without harming the cells it infected. They identified a class of derivatives (collectively named PPs, based on the presence of phenanthrene and pyrrolidine groups within the structures) with high antitubercular effects and low toxicity.
For several derivatives, a standard measure of antibacterial effect, known as the minimum inhibitory concentration (MIC), was lower (i.E.: better) than for the current first-line TB drugs in XDR strain-infected cell culture. In a mouse model, 4 weeks of treatment with one derivative, called PP1S, significantly reduced the burden of TB infection compared to the control group. Neither PP1S nor a second derivative, PP2S, produced any clinical side effects in healthy rats after two weeks of high-dose treatment. No adverse effects were seen after four weeks of intermediate-dose therapy with PP2S.
One concern with antibiotic treatment is off-target killing of other bacteria, including those in the gut. After one week of treatment with PP2S, no significant changes were seen in the mouse gut microbiome, versus multiple changes observed after treatment with other TB drugs. The extremely selective effect on M. Tuberculosis is likely due to the target of the PPs, which the authors showed was probably a gene called PE_PGRS57. This gene appears to be found in very few other species of bacteria, including multiple other Mycobacterium species.
Currently, treatment of MDR TB requires over a year of therapy with a cocktail of antibiotics, each with important side effects. "While further testing will be required, the low effective dose and high level of safety in these early tests indicate that these new drugs are likely to be important alternatives to the current regimen for treatment of tuberculosis," Song said.
Song adds, "A new class of PP derivatives is a Mycobacterium tuberculosis-targeted antimicrobial with microbiome-safe properties."
Trends In Discovery Of New Drugs For Tuberculosis Therapy
Lienhardt, C. Et al. Global tuberculosis control: lessons learnt and future prospects. Nat. Rev. Microbiol. 10, 407–416 (2012).
Paulson, T. Epidemiology: a mortal foe. Nature 502, S2–S3 (2013).
Post, F. A. Et al. Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. J. Infect. 68, 259–263 (2013).
World Health Organization. WHO Global Tuberculosis Report 2013, http://www.Who.Int/tdr/news/2013/global-TB-report/en/ (2013).
Lienhardt, C. Et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J. Infect. Dis. 205, S241–S249 (2012).
Green, K. D. & Garneau-Tsodikova, S. Resistance in tuberculosis: what do we know and where can we go? Front. Microbiol. 4, 208 (2013).
Sotgiu, G., Spanevello, A. & Migliori, G. B. In vitro susceptibility testing and totally drug-resistant tuberculosis. Eur. Respir. J. 42, 292 (2013).
Udwadia, Z. F., Amale, R. A., Ajbani, K. K. & Rodrigues, C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 54, 579–581 (2012).
Velayati, A. A. Et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136, 420–425 (2009).
Migliori, G. B. Et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin. Infect. Dis. 54, 1379–1380 (2012).
Riccardi, G., Pasca, M. R. & Buroni, S. Mycobacterium tuberculosis: drug resistance and future perspectives. Future Microbiol. 4, 597–614 (2009).
Vilchèze, C. & Jacobs, W. R. Jr. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu. Rev. Microbiol. 61, 35–50 (2007).
Wang, L.-Q., Falany, C. N. & James, M. O. Triclosan as a substrate and inhibitor of 3′-phosphoadenosine 5′-phosphosulfate-sulfotransferase and UDP-glucuronosyl transferase in human liver fractions. Drug Metab. Dispos. 32, 1162–1169 (2004).
Freundlich, J. S. Et al. Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. ChemMedChem 4, 241–248 (2009).
Matviiuk, T. Et al. Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis. Eur. J. Med. Chem. 71, 46–52 (2014).
Hartkoorn, R. C. Et al. Towards a new tuberculosis drug: pyridomycin - nature's isoniazid. EMBO Mol. Med. 4, 1032–1042 (2012).
Scorpio, A. Et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41, 540–543 (1997).
Shi, W. Et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333, 1630–1632 (2011).
Saguy, M. Et al. Ribosomal protein S1 influences trans-translation in vitro and in vivo. Nucleic Acids Res. 35, 2368–2376 (2007).
Zhang, Y. Et al. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52, 790–795 (2003).
McDermott, W. & Tompsett, R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc. 70, 748–754 (1954).
McCune, R. M., Feldmann, F. M., Lambert, H. P. & McDermott, W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123, 445–468 (1966).
Wolucka, B. A. Biosynthesis of D-arabinose in mycobacteria—a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J. 275, 2691–2711 (2008).
Telenti, A. Et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. 3, 567–570 (1997).
Telenti, A. Et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341, 647–650 (1993).
Sensi, P. History of the development of rifampin. Rev. Infect. Dis. 5, S402–S406 (1983).
Mukhopadhyay, J. Et al. The RNA polymerase "switch region" is a target for inhibitors. Cell 135, 295–307 (2008).
Sensi, P. Approaches to the development of new antituberculosis drugs. Rev. Infect. Dis. 11, S467–S470 (1989).
North, E. J., Jackson, M. & Lee, R. E. New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics. Curr. Pharm. Des. 20, 4357–4378 (2014).
Zumla, A., Nahid, P. & Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388–404 (2013).
Palomino, J. C. & Martin, A. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio. Curr. Med. Chem. 20, 3785–3796 (2013).
Nunn, A., Phillips, P. P. & Abubakar, I. Treatment of pulmonary tuberculosis. Curr. Opin. Pulm. Med. 19, 273–279 (2013).
Mahajan, R. Bedaquiline: First FDA-approved tuberculosis drug in 40 years. Int. J. Appl. Basic Med. Res. 3, 1–2 (2013).
Andries, K. Et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307, 223–227 (2005).
Chan, B., Khadem, T. M. & Brown, J. A review of tuberculosis: focus on bedaquiline. Am. J. Health Syst. Pharm. 70, 1984–1994 (2013).
Haagsma, A. C. Et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother. 53, 1290–1292 (2009).
Chahine, E. B., Karaoui, L. R. & Mansour, H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann. Pharmacother. 48, 107–115 (2014).
Singh, R. Et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322, 1392–1395 (2008).
Manjunatha, U., Boshoff, H. I. & Barry, C. E. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun. Integr. Biol. 2, 215–218 (2009).
Diacon, A. H. Et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 54, 3402–3407 (2010).
Gler, M. T. Et al. Delamanid for multidrug-resistant pulmonary tuberculosis. New Engl. J. Med. 366, 2151–2160 (2012).
Zhang, Q., Liu, Y., Tang, S., Sha, W. & Xiao, H. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China. Cell Biochem. Biophys. 67, 957–963 (2013).
Munsiff, S. S., Kambili, C. & Ahuja, S. D. Rifapentine for the treatment of pulmonary tuberculosis. Clin. Infect. Dis. 43, 1468–1475 (2006).
Chan, J. G., Bai, X. & Traini, D. An update on the use of rifapentine for tuberculosis therapy. Expert Opin. Drug Deliv. 11, 421–431 (2014).
Dooley, K. E. Et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin. Pharmacol. Ther. 91, 881–888 (2012).
Tahlan, K. Et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 1797–1809 (2012).
Sacksteder, K. A., Protopopova, M., Barry, C. E. 3rd, Andriesm, K. & Nacy, C. A. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol. 7, 823–837 (2012).
Owens, C. P. Et al. The Mycobacterium tuberculosis secreted protein Rv0203 transfers heme to membrane proteins MmpL3 and MmpL11. J. Biol. Chem. 288, 21714–21728 (2013).
Grzegorzewicz, A. E. Et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol. 8, 334–341 (2012).
La Rosa, V. Et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56, 324–331 (2012).
Stanley, S. A. Et al. Identification of novel inhibitors of M. Tuberculosis growth using whole cell based high-throughput screening. ACS Chem. Biol. 7, 1377–1384 (2012).
Lun, S. Et al. Indoleamides are active against drug-resistant Mycobacterium tuberculosis. Nat. Commun. 4, 2907 (2013).
Blair, J. M. & Piddock, L. J. Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update. Curr. Opin. Microbiol. 12, 512–519 (2009).
Poce, G. Et al. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS ONE 8, e56980 (2013).
Wolucka, B. A. Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J. 275, 2691–2711 (2008).
Riccardi, G. Et al. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. Appl. Microbiol. Biotechnol. 97, 8841–8848 (2013).
Makarov, V. Et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801–804 (2009).
Neres, J. Et al. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci. Transl. Med. 4, 150ra121 (2012).
Pasca, M. R. Et al. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob. Agents Chemother. 54, 1616–1618 (2010).
Lechartier, B., Hartkoorn, R. C. & Cole, S. T. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 5790–5793 (2012).
Makarov, V. Et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol. Med. 6, 372–383 (2014).
Christophe, T. Et al. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5, e1000645 (2009).
Magnet, S. Et al. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb) 90, 354–360 (2010).
Wang, F. Et al. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc. Natl Acad. Sci. USA 110, E2510–E2517 (2013).
Shirude, P. S. Et al. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J. Med. Chem. 56, 9701–9708 (2013).
Batt, S. M. Et al. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl Acad. Sci. USA 109, 11354–11359 (2012).
Orme, I. M. Vaccine development for tuberculosis: current progress. Drugs 73, 1015–1024 (2013).
How Do Antibiotics Work? What To Know As You Sift Through Information
Your browser is not supportedusatoday.Comusatoday.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.
Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on usatoday.Com
Comments
Post a Comment